ArticleACS medicinal chemistry letters2025
Design, Synthesis, and Biological Evaluation of Sulfonamide Derivatives as Potent CDK9 Inhibitors.
Yifang Liu, Zexu Wang, Yifan Xu, Liyan Yang, Xiaolei Yang, Zhiyu Li, Jinlei Bian, Jubo Wang, Lixia Pan, Tizhi Wu
Erratum issuedAbstract read
In one paragraphArticle in ACS medicinal chemistry letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
10 authors.
Yifang LiuJiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Zexu WangJiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Yifan XuJiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Liyan YangNational Key Laboratory of Non-food Biomass Energy Technology, Guangxi Key Laboratory of Marine Natural Products and Combinatorial Biosynthesis Chemistry, Guangxi Academy of Sciences, Nanning 530007, China.
Xiaolei YangJiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Zhiyu LiJiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.ORCID https://orcid.org/0000-0001-6492-9511 Jinlei BianJiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.ORCID https://orcid.org/0000-0003-4552-1195 Jubo WangJiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Lixia PanNational Key Laboratory of Non-food Biomass Energy Technology, Guangxi Key Laboratory of Marine Natural Products and Combinatorial Biosynthesis Chemistry, Guangxi Academy of Sciences, Nanning 530007, China.ORCID https://orcid.org/0000-0002-9360-5492 Tizhi WuJiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.ORCID https://orcid.org/0009-0005-5061-3520 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Targeting CDK9 has become an attractive strategy for antitumor drug development. To obtain CDK9 inhibitors with high activity and safety, we designed and synthesized a series of sulfonamide derivatives as CDK9 inhibitors based on BAY1143572, the first selective CDK9 inhibitor to enter clinical trials. Among them, the representative compound
Indexed as
antitumorCDK9 inhibitorsMcl-1sulfonamide
Identifiers
PMID40959249
PMCPMC12434516
What OpenQuestion holds
Textmetadata
Read underepoch 390